Table 1.
Disease characteristics of SLE patients
| SLE (n = 30) | |
|---|---|
| ACR criteria, n (%) | |
| Malar rash | 13 (43%) |
| Discoid rash | 6 (20%) |
| Photosensitivity | 12 (40%) |
| Oral ulcers | 9 (30%) |
| Arthritis | 20 (66%) |
| Serositis | 16 (53%) |
| Renal disorder | 13 (43%) |
| Neurological disorder | 1 (3%) |
| Hematological disorder | 23 (77%) |
| Immunological disorder | 26 (87%) |
| Antinuclear antibody | 30 (100%) |
| Duration of disease, months | 146 (49 to 209) |
| SLEDAI | 4 (2 to 4) |
| Anti-dsDNA, Farr | 20 (6 to 140) |
| Complement C3, g/l | 0.89 (0.74 to 1.06) |
| Complement C4, g/l | 0.12 (0.09 to 0.17) |
| C-reactive protein, mg/l | 1.8 (0.5 to 4.5) |
| Creatinine Clearance, ml/min | 106 (93 to 131) |
| Prednisolone use, n (%) | 19 (63%) |
| Dose, mg/day | 7.5 (5 to 10) |
| Hydroxychloroquine use, n (%) | 15 (50%) |
| Dose, mg/dag | 400 (400 to 400) |
| Azathioprine use, n (%) | 11 (37%) |
| Dose, mg/day | 100 (50 to 150) |
Unless stated otherwise, data are expressed as median (25 to 75%). ACR, American College of Rheumatology; SLEDAI, SLE disease activity index; anti-dsDNA, anti-double stranded DNA.